A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 450 participants.

Also called NCT07570940

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 450 participants (planned count) (from the registry)
Sponsor
  • Mayo Clinic Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07570940
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07570940. Randomized; double masking; primary purpose treatment. Start 2026-09-14 (anticipated); primary completion 2030-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study Of Stellate Ganglion Blockade With Liposomal Bupivacaine In Preventing Atrial Fibrillation After Isolated Coronary Artery Bypass Grafting Surgery
Intervention (Drug)
Liposomal bupivacaine
Intervention (Drug)
Placebo
Lead sponsor
Mayo Clinic (class: other)

Record details

Record id
cardio:ct-nct07570940
Content hash
8d881211e9267de9fd096088b234aa80234dc34e6b45199336023fa94830ae92